Results 21 to 30 of about 9,113,589 (351)

Multicentric Cutaneous Crohn's Disease: A Case Report and Review of Literature

open access: yesCanadian Journal of Gastroenterology, 1990
A patient presented with skin lesions at sites not contiguous with Crohn's disease of the bowel and with specific histological features of Crohn's disease occurring two weeks from the onset of bowel symptoms.
Robert Prokopetz   +3 more
doaj   +1 more source

Infliximab maintenance therapy for fistulizing Crohn's disease.

open access: yesNew England Journal of Medicine, 2004
BACKGROUND Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas.
B. Sands   +17 more
semanticscholar   +1 more source

Adenocarcinoma arising from chronic perianal crohn's disease: a case report

open access: yesThe Pan African Medical Journal, 2015
Malignant transformation of perineal fistula in Crohn's disease has rarely been reported. We report a case of Crohn's disease with recurrent perineal fistulas.
Hanane Massit   +5 more
doaj   +1 more source

Primary colonic MALT lymphoma associated with Crohn's disease: Case report and review of the literature

open access: yesClinical Case Reports, 2023
Key Clinical Message To date, the pathogenic mechanisms of the association between Crohn's disease and MALT lymphoma are ambiguous and yet remain to be elucidated.
Amira Hmidi   +4 more
doaj   +1 more source

Adalimumab - an effective and promising treatment for patients with fistulizing Crohn's disease: a case series

open access: yesJournal of Medical Case Reports, 2011
Introduction Crohn's disease is a chronic inflammatory bowel disease of unknown etiology which may affect any part of the bowel. Fistulas are a common and often serious complication of Crohn's disease. The treatment for fistulizing Crohn's disease can be
Simopoulos Konstantinos   +7 more
doaj   +1 more source

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

open access: yesNew England Journal of Medicine, 2003
BACKGROUND Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab.
F. Baert   +6 more
semanticscholar   +1 more source

The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update.

open access: yesJournal of Crohn's & Colitis, 2020
OBJECTIVE We aimed to provide an evidence-supported update of the ECCO-ESPGHAN guideline on the medical management of paediatric Crohn's disease [CD]. METHODS We formed 10 working groups and formulated 17 PICO-structured clinical questions [Patients ...
P. V. van Rheenen   +24 more
semanticscholar   +1 more source

Esophageal Crohn's Disease Treated “Topically” with Swallowed Aerosolized Budesonide

open access: yesCase Reports in Medicine, 2010
Proximal Crohn's disease, involving the esophagus, the stomach, the duodenum, and the proximal jejunum, is uncommon. Treatment for proximal Crohn's disease is based on data derived from case series than from controlled trials.
Petros Zezos   +4 more
doaj   +1 more source

Uveitis as first manifestation of probably Crohn's disease

open access: yesRevista Brasileira de Oftalmologia, 2012
Extraintestinal manifestations of Crohn's disease are common. Although ocular complications of Crohn's disease are infrequent, most ocular manifestations include iritis, uveitis, episcleritis, scleritis and conjuntivitis.
Ieda Maria Alexandre Barreira   +4 more
doaj   +1 more source

Infliximab for the treatment of fistulas in patients with Crohn's disease.

open access: yesNew England Journal of Medicine, 1999
BACKGROUND Enterocutaneous fistulas are a serious complication of Crohn's disease and are difficult to treat. Infliximab, a chimeric monoclonal antibody to tumor necrosis factor alpha, has recently been developed as a treatment for Crohn's disease.
Tephan   +18 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy